Per O. Gisleskog
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.
Journal: British journal of clinical pharmacology
Published: October 22, 2025
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: February 18, 2025
Evaluation of the Effect of Loperamide on the Cardiac Repolarization Interval Using Exposure-Response Analysis.
Journal: Clinical and translational science
Published: July 30, 2024
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Journal: Clinical pharmacokinetics
Published: March 25, 2021
Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF.
Journal: Pharmaceutical research
Published: October 10, 2019
Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome.
Journal: Clinical and translational science
Published: September 05, 2019
Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
Journal: British journal of clinical pharmacology
Published: July 20, 2018
Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Journal: Clinical pharmacokinetics
Published: May 17, 2017
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 30, 2014
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.
Journal: Journal of pharmaceutical sciences
Published: June 28, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026